Prostate Cancer News and Research

Latest Prostate Cancer News and Research

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation. The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

1 Jul 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

29 Jun 2010

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs, according to researchers at Duke University Medical Center. Researchers also found that higher doses of the drugs were associated with lower risk of recurrence.

29 Jun 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.

28 Jun 2010

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zila, leader in the prevention and detection of oral diseases, today introduced an angled exam mirror as part of the ViziLite Plus oral lesion identification and marking system. The autoclavable mirror attaches to the top of the ViziLite Plus lightstick retractor, enhancing dental professionals' ability to see oral lesions during a comprehensive oral cancer screening procedure.

28 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."

28 Jun 2010

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday).

25 Jun 2010

AVIS donates health research project focuses on cancer biomarkers

The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.

24 Jun 2010

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

The Cancer Prevention and Research Institute of Texas has granted $3.7 million to Rice University researchers to fund an innovative cancer diagnostics program.

24 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Monitoring can be the best treatment for men with prostate cancer of the low-risk type, according to a study now being published in the Journal of the National Cancer Institute. The lead author is Pär Stattin, a urologist at Umeå University.

23 Jun 2010

Recent study shows drinking coffee protects against head and neck cancer

Data on the effects of coffee on cancer risk have been mixed. However, results of a recent study add to the brewing evidence that drinking coffee protects against cancer, this time against head and neck cancer.

23 Jun 2010

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospital Centre) in Pointe - Pitre (urology department, University of the French West Indies and Guiana) and from the Center for Analytical Research and Technology (University of Li-ge, Belgique), show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer.

23 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

AVIS donates health research project focuses on cancer biomarkers

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

UK cancer survival rates increase at 3% each year

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Recent study shows drinking coffee protects against head and neck cancer

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

Ostarine increases muscle mass and strength in postmenopausal women: Study

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in